Get the Stockscreener App
27.09
5.45%
1.40
After Hours:
27.18
0.09
+0.33%
Ascentage Pharma Group International Adr stock is traded at $27.09, with a volume of 1,640.
It is up +5.45% in the last 24 hours and up +10.89% over the past month.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
See More
Previous Close:
$25.69
Open:
$27.1
24h Volume:
1,640
Relative Volume:
0.50
Market Cap:
$2.53B
Revenue:
$80.00M
Net Income/Loss:
$-172.98M
P/E Ratio:
-13.95
EPS:
-1.9419
Net Cash Flow:
$164.80M
1W Performance:
+2.00%
1M Performance:
+10.89%
6M Performance:
-26.57%
1Y Performance:
+39.28%
1-Day Range:
$27.00
$27.20
1-Week Range:
$24.81
$27.20
52-Week Range:
$18.52
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Name
Ascentage Pharma Group International Adr
Sector
Industry
Phone
-
Address
-
Compare AAPG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
27.09 | 2.40B | 80.00M | -172.98M | 164.80M | -1.9419 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Dec-04-25 | Initiated | Oppenheimer | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-10-25 | Initiated | BTIG Research | Buy |
| Nov-05-25 | Initiated | Piper Sandler | Overweight |
| Mar-27-25 | Initiated | JP Morgan | Overweight |
View All
Ascentage Pharma Group International Adr Stock (AAPG) Latest News
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Short Interest Update - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpShould You Buy? - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownWhat's Next? - MarketBeat
Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Ascentage Pharma Group International (NASDAQ:AAPG) Upgraded at China Intl Cap - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 12%Should You Buy? - MarketBeat
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Sahm
Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume IncreaseHere's Why - MarketBeat
Truist Financial Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail
BTIG Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail
Earnings Scheduled For March 25, 2026 - Sahm
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates - GlobeNewswire Inc.
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 20.3%Should You Buy? - marketbeat.com
Short Interest in Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Increases By 546.9% - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 7.7%Here's Why - MarketBeat
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 - Sahm
Ascentage Pharma Sets March 25 Board Meeting on 2025 Results and Potential Final Dividend - TipRanks
Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Irhythm Technologies (IRTC) - The Globe and Mail
Ascentage Pharma Ramps Up Investor Outreach With Three U.S. Conferences - TipRanks
Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target - Finviz
Ascentage Pharma to Present at Guggenheim Biotech Summit as Late-Stage Oncology Pipeline Expands - The Globe and Mail
Ascentage Pharma Wins China IND Clearance for Next-Gen BTK Degrader APG-3288 - TipRanks
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Sahm
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Resmed (RMD) and Sanofi (OtherSNYNF) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Increase in Short Interest - Defense World
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) - The Globe and Mail
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World
Ascentage Pharma Group International Adr Stock (AAPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):